INTRODUCTION
Ependymomas account for 10% of intracranial tumors in children and 4% of brain and spinal cord tumors in adults (Chamberlain, 2003; Rudà et al., 2008) . Genomic studies have subdivided supratentorial (ST), posterior fossa (PF) and spinal (SP) ependymomas into clinically meaningful and molecularly distinct subgroups (Johnson et al., 2010; Mack et al., 2014; Pajtler et al., 2015; Parker et al., 2014; Taylor et al., 2005; Witt et al., 2011) . Despite these insights, all ependymomas are similarly treated with surgery and radiotherapy. Chemotherapy is not used routinely to treat ependymoma because it is largely ineffective (Bouffet and Foreman, 1999; Merchant et al., 2009 ).
Recent next-generation sequencing studies have discovered recurrent chromosomal translocations in a subset of ST-ependymomas that generate distinct fusion oncogenes . Seventy-two percent of ST-ependymomas contain C11orf95-RELA fusions (Pajtler et al., 2015; Parker et al., 2014) . Patients with these tumors have a 5-year progression-free survival of <30% (hereafter termed the ST-ependymoma [EPN]-RELA subtype). A further 10% of ST-ependymomas contain either C11orf95-YAP1, YAP1-MAMLD1, or YAP1-FAM118B fusions (ST-EPN-YAP1 subtype) and have a much better 5-year progression-free survival of 66% (Pajtler et al., 2015; Parker et al., 2014) . RELA and YAP1 fusions are highly restricted to ST-ependymomas, supporting the notion that regional neural cell types are uniquely susceptible to specific genetic mutations (Johnson et al., 2010; Mohankumar et al., 2015; Taylor et al., 2005) . The remaining 18% of ST-ependymomas are subependymomas that lack fusion genes and have an excellent clinical outcome (Pajtler et al., 2015; Parker et al., 2014) .
We showed recently that the two most common C11orf95-RELA fusions (RELA FUS1 and RELA FUS2 ) and C11orf95-YAP1 (but not C11orf95, RELA, or YAP1 alone) can transform embryonic mouse neural stem cells ex vivo . Although expression of RELA FUS1 was shown to activate nuclear factor κB (NF-κB) signaling, whether this is required for transformation and whether fusions can drive ependymomagenesis de novo in the brain is not known. To test this, we used the RCAS/tv-a system to deliver the RELA FUS1 fusion or fusion variants engineered to contain mutations in critical portions of RELA to Nestin-, glial fibrillary acidic protein (GFAP)-, or BLBP-expressing cells in the mouse brain. Neither C11orf95 nor RELA alone were sufficient to drive tumorigenesis. Expression of RELA FUS1 in our system upregulated a broad array of genes that included an NF-κB-associated transcriptional signature; however, RELA FUS1 mutants with selective mutation of the Rel homology domain (RHD) as well as constitutively active RELA mutants failed to induce brain tumor formation. The data suggest that RELA FUS1 is adequate to drive EPN formation de novo in the brain. The oncogenic effect of RELA FUS1 requires the Ser 486, but not Ser 746, phosphorylation site in the fusion protein and produces biologic effects that are not restricted to NF-κB. brain cells using Nestin (N)/tv-a mice (Figures 1A and S1; . Fifty-two  percent and 92% of mice injected with RCAS-RELA FUS1 or RCAS-RELA FUS1 -HA, respectively, but not a control, developed tumors within 2 months of injection (Figures 1A-1C; Table S1A ). In stark contrast, RCAS-HA-RELA, RCAS-RELA-HA, or RCASC11orf95-HA failed to generate tumors, confirming our prior observations that RELA FUS1 , but neither translocation partner gene alone, is competent to drive tumorigenesis (Figures 1A-1C and S1; Parker et al., 2014) . Notably, although CDKN2A (INK4A-ARF) is deleted in some ST-EPN-RELA tumors and enhances platelet-derived growth factor (PDGF)-induced glioma formation in mice, RELA FUS1 -induced tumorigenesis neither required, nor was it accelerated by, ink4a-Arf deletion in mice (Figures 1B and 1C ; Table S1B ; Fomchenko et al., 2011; Ozawa et al., 2014; Pajtler et al., 2015) .
RELA FUS1 -Induced Mouse Tumors Recapitulate ST-EPN Histology
RELA FUS1 -induced tumors were well circumscribed, predominantly intra-ventricular tumors that displayed several histological features characteristic of ependymoma, including a biphasic architectural pattern of dense cell clusters alternating with hypocellular regions and relatively little necrosis (Figures 2A and S2A) but no canonical ependymal rosettes and pseudorosettes, although similar structures were sometimes observed ( Figure 2B ). RELA FUS1 -induced tumors also contained a network of delicate branching capillaries similar to that observed in our ex vivo RELA FUS1 -induced tumor model and the vascular variant of human ST-ependymomas ( Figure 2B ; Figarella-Branger et al., 2016; Godfraind et al., 2012; Rousseau et al., 2007) . These morphological findings were obviously distinct from both astrocytic and oligodendrocytic glioma mouse models and human glioblastoma (GBM) presenting an infiltrative growth pattern and glomeruloid microvascular formation . Immunostaining and electron microscopy of RELA FUS1 -induced tumors identified additional features common to human ependymomas, including expression of GFAP and Olig2 and interdigitating tumor cell processes (Figures 2C and 2D and S2E and S2F; Liberski, 1996; Otero et al., 2011) . Furthermore, we showed previously that human ST-EPN-RELA tumors display intense nuclear RELA immunoreactivity . The same immunohistochemical feature was displayed by our de novo RELA FUS1 -induced tumors but not by similarly generated PDGFA-or shNfl (GPT53N)-driven mouse gliomas ( Figure 3A ). These observations were further validated in a cohort of human ST-(n = 23), PF-(n = 49), and SPependymomas (n = 48) and GBMs (n = 30)  Tables S2A-S2C ). Thus, our RELA FUS1 -induced brain tumors recapitulate the principal growth, morphological, and immunohistochemical features of human ST-EPN-RELA tumors.
RELA FUS1 -Induced Mouse Tumors Express a Human ST-EPN-RELA-like Transcriptome
To further assess the fidelity of the RELA FUS1 -EPN mouse model, we performed RNA sequencing (RNA-seq) analysis of these tumors and compared their transcriptomes with those of normal mouse brain and PDGFA-driven mouse gliomas (Table S3) . Principalcomponent analysis clearly segregated RELA FUS1 -ependymoma, PDGFA-driven glioma, and normal brain transcriptomes, confirming the distinct biologies of these tissues ( Figure  4A ). Next, to test whether RELA FUS1 -driven mouse transcriptomes recapitulate those of human ST-EPN-RELA, we compared their transcriptomes using cross-species gene set enrichment analysis (GSEA) (Supplemental Experimental Procedures). Gene sets that define human ST-ependymoma, and in particular ST-EPN-RELA, but not human PF-or SPependymoma, were significantly enriched in mouse RELA FUS1 -driven tumor transcriptomes (Figures 4B-4E; Pajtler et al., 2015; Taylor et al., 2005) . Thus, in addition to displaying the morphologic and immunophenotypic characteristics of ST-EPN-RELA, RELA FUS1 -ependymomas also recapitulate the transcriptome of human ST-EPN-RELA.
We showed previously that RELA FUS1 translocates spontaneously to the nucleus of mouse neural stem cells to activate the transcription of a large number of genes, including NF-κB target genes . In keeping with these data, genes that were significantly upregulated in de novo RELA FUS1 -induced mouse ependymomas relative to normal brain included 52% (n = 158 of 302) of validated NF-κB target genes (false discovery rate [FDR] p = 4.7 × 10 −7 ), and GSEA identified "TNFA_signaling_via_NFKB" as one of the most enriched gene sets in these tumors (FDR, q value 6.39 × 10 −43 ). Furthermore, hierarchical clustering using validated NF-κB target genes alone readily segregated de novo mouse RELA FUS1 -EPN (EP), PDGFA-driven glioma (GM) and normal mouse brain (NB) transcriptomes ( Figure 4F ). Thus, RELA FUS1 activates NF-κB target gene transcription following de novo tumor formation in vivo as well as in neural stem cells in vitro.
RELA FUS1 Induces an Aberrant Non-Canonical NF-κB Transcriptional Cassette
Although overexpression of wild-type RELA in neural stem cells activates gene transcription, this is restricted to NF-κB target genes and does not promote malignant transformation (Figures 1B and 1C ; Tables S1A-S1D; Parker et al., 2014) . Thus, aberrant NF-κB signaling appears to be associated with, but not sufficient, to drive RELA FUS1 -induced tumorigenesis. Therefore, to better understand how RELA FUS1 drives transformation, we looked for non-NF-κB target genes that were dysregulated in both our ex vivo and de novo RELA FUS1 -induced mouse ependymomas. Nine thousand nine hundred and sixty-five genes were significantly up-or downregulated in either our ex vivo neural stem cell or de novo RELA FUS1 -induced mouse brain tumors relative to mouse normal neural stem cells and brain, respectively (p < 0.05 FDR). A significant number of these genes was commonly dysregulated in both tumors, including 13% that were upregulated (n = 1,271 of 9,965) and 4% that were downregulated (n = 400 of 9,965) in both tumor models (p = 2.3 × 10 −6 for overlap) (Table S4 ). Only 6% of these genes (n = 102 upregulated, n = 1 downregulated) are known NF-κB targets (Table S4A) . GSEA segregated the remaining 1,568 "non-NF-κB" target genes into nine broad classes (Table S4B) . Remarkably, we showed previously that six of these classes are dysregulated when mouse neural stem cells are transformed by non-fusion EPN oncogenes (Mohankumar et al., 2015) . These included negative enrichment of synaptogenesis and vesicle trafficking regulators (e.g., INTRACELLULAR_VESICLE, n = 137 of 1,259, FDR q value = 2.84 × 10 −51 ), consistent with our observation that these genes are selectively deleted during ST-EPN tumorigenesis (Mohankumar et al., 2015) . The five other gene classes commonly enriched with those in non-RELA FUS1 EPN included stem cell function and neuronal differentiation (e.g., REGULATION_OF_CELL_DIFFERENTIATION, n = 160 of 1,492, FDR q value = 3.20 × 10 −59 ), immunity and inflammation (e.g., REGULATION_OF_CYTOKINE_PRODUCTION, n = 114 of 563, FDR q value = 8.71 × 10 −69 ), the epigenome (SILENCED_BY_METHYLATION, n = 67 of 282, FDR q value = 6.14 × 10 −47 ), and those associated with other cancer types. Notably, this latter class included positive enrichment of genes associated with the mesenchymal subtype of glioblastoma (GLIOBLASTOMA_MESENCHYMA, n = 95 of 216, FDR q value = 2.26 × 10 −95 ). By addition to these six broad classes, RELA FUS1 -induced transformation also enriched the expression of genes controlling cell-cell adhesion (e.g., BIOLOGICAL_ADHESION, n = 155 of 1,032, FDR q value = 4.27 × 10 −75 ) and downregulated genes controlling the transmembrane transport of ions (e.g., ION_TRANSPORT, n = 45 of 1,262, FDR q value = 1.23 × 10 −12 ) that we did not observe during the formation of non-RELA FUS1 EPN (Mohankumar et al., 2015) . Together, these data suggest that all forms of ST-ependymomagenesis require dysregulation of synaptogenesis and vesicle trafficking, stem cell function and neuronal differentiation, immunity and inflammation, the epigenome, and functions associated with other cancer types; however, dysregulation of cell-cell adhesion and ion transport might be associated more selectively with RELA FUS1 -induced transformation.
Because loss of Ink4a-Arf did not affect the tumor latency of our RELA FUS1 -induced ependymomas, we investigated the dysregulation of alternative pathways. Accumulation of TP53 is very frequent in human ST-EPN-RELA tumors and associated with a poor prognosis, although this gene mutation is rare (Tzaridis et al., 2016) . Furthermore, the accumulated TP53 is thought to be functionally impaired in ependymomas (Gaspar et al., 2006; Tzaridis et al., 2016; Verstegen et al., 2002) . Therefore, we focused on Trp53 status in the mouse tumors. Consistent with frequent accumulation of TP53 in human RELA FUSpositive cases (Tzaridis et al., 2016) , evident upregulation of the Trp53 pathway and elevated Trp53 mRNA expression were observed in RELA FUS1 -induced tumors in both N/tv-a and N/tv-a; Ink4a-Arf −/− mice ( Figures S4A-S4 ). Thus, it is possible that the effect of Ink4a-Arf loss in RELA FUS1 -induced EPN formation was blurred by dysregulation of the TP53 pathway in our model, leading to no survival difference between the genetic backgrounds ( Figures 1B and 1C ).
Serine-486 of RELA FUS1 (Corresponding to Serine-276 of RELA) Is Critical to Drive Tumorigenesis
The aberrant juxtaposition of genes within fusion proteins following chromosomal translocation may result in the uncontrolled activation of fusion partners or the acquisition of novel functions (Mertens et al., 2015) . Our transcriptomic analyses of RELA FUS1 -driven tumors suggest that this fusion activates NF-κB signaling and a series of other cell pathways. Therefore, to further dissect the NF-κB-and non-NF-κB-related transforming functions of RELA FUS1 , we created a series of mutant forms of wild-type RELA and RELA FUS1 and tested the capacity of these constructs to drive tumorigenesis in our RCAS/tv-a system in vivo. Phosphorylation of Ser-276 and Ser-536 within the Rel homology and transactivation domains, respectively, has been reported to promote RELA transcriptional activity ( Figure 1A ; Chen and Greene, 2004; Hoesel and Schmid, 2013; Huang et al., 2010) ; however, introduction of phosphomimetic mutants of these residues (RELA-S276E, RELA-S536E, or combined RELA-S276E/S536E) into the brains of N/tv-a and N/tv-a;Ink4a-arf −/− neonatal mice failed to drive tumorigenesis (Figures 1A and S5A ; Tables S1A and S1B). Thus, consistent with our studies of overexpressed wild-type RELA , constitutively active RELA is not competent to drive ependymomagenesis.
We next created a series of RELA FUS1 mutants and tested the ability of these to drive ependymomagenesis in the brains of N/tv-a and N/tv-a;Ink4a-arf −/− neonatal mice ( Figures   1A and S5B-S5D) . A serine-glutamine substitution at Ser-486 of RELA FUS1 (corresponding to Ser-276 in the Rel homology domain of RELA) markedly reduced the transforming capacity of RELA FUS1 ( Figures 1A and 5A-5C ; Tables S1A-S1C); RELA FUS1 -S486E formed no tumors in 14 N/tv-a neonatal brains compared with a tumor penetrance of 92% (n = 33 of 36) in mice injected with RELA FUS1 (log ratio, p = 0.0009) ( Figure 5C ; Tables S1A and S1C). RELA FUS1 -S486E-driven tumor penetrance was also much reduced in N/tva;Ink4a-arf −/− neonatal mice (8%, n = 1 of 12) compared with 86% (n = 24 of 28) driven by RELA FUS1 (log ratio, p = 0.0095) ( Figure 5C ; Tables S1B and S1C). In contrast, a serineglutamine substitution at Ser-746 (corresponding to Ser-536 of RELA) did not reduce tumorigenesis in either N/tv-a or N/tv-a;Ink4a-arf −/− neonatal mice ( Figures 1A and 5A-5C ; Tables S1A-S1C). Constructs harboring both of these substitutions (RELA FUS1 -S486E/ S746E: EE) failed to drive tumorigenesis in the N/tv-a neonatal brain and drove tumors with a penetrance of only 12% (n = 4 of 33) in N/tv-a;Ink4a-arf −/− neonatal mice (Figures 5A-5C ; Tables S1A-S1C), suggesting that S486E had a negative effect on the brain tumorforming capacity of RELA FUS1 . Two additional constructs carrying serine-alanine substitutions at these same residues (RELA FUS1 -S486A and RELA FUS1 -S486A/S746A: AA) also abolished and markedly reduced RELA FUS1 -driven ependymomagenesis in N/tv-a (S486A, log rank test, p = 0.0006; S486A/S746A, log rank test, p = 0.1731) and N/tva;Ink4a-arf −/− (S486A, log-rank test, p = 0.0004; S486A/S746A, log-rank test, p = 0.0024) neonatal mouse brains, respectively (Figures 5A-5C ; Tables S1A-S1C), whereas RELA FUS1 -S746A did not affect tumorigenesis. Thus, Ser-486, but not Ser-746, appears to be critical for RELA FUS1 -driven ependymomagenesis.
Acetylation of RELA has also been reported to regulate NF-κB activity (Huang et al., 2010) . Acetylation of lysine-310 (K310) has been reported to promote full transcriptional activity (Chen et al., 2002; Huang et al., 2010) , and K221/K218 acetylation enhances DNA binding and prevents nuclear export. To test the importance of these residues in RELA FUS1 -driven tumorigenesis, we generated lysine-to-arginine unacetylatable mutants in the residues corresponding to K218, K221, and K310R of RELA (RELA FUS1 -K428R/K431R/K520R: 3KR; Figures 1A, S5B , and S5E; Chen et al., 2002) . RELA FUS1 -3KR drove ependymomas with high penetrance in N/tv-a (84%, n = 21/25) and N/tv-a;Ink4a-Arf −/− (83%, n = 29 of 35) mice, indicating that acetylation of these residues is dispensable for RELA FUS1 -driven tumorigenesis (Figures 5A-5C ; Tables S1A-S1C).
Disruption of Cell-Cell Adhesion Is a Critical Component of RELA FUS1 -Driven Tumorigenesis
We reasoned that comparing the transcriptomes driven by RELA FUS1 mutants that did or did not drive tumorigenesis might pinpoint cell functions that are critically associated with RELA FUS1 -driven transformation. Multi-dimensional scaling (MDS) using NF-κB target genes as input (Tables S5 and S6 )clearly segregated NIH 3T3/tv-a cells transduced with tumor-forming vectors (RELA FUS1 , RELA FUS1 -S746E, and RELA FUS1 -3KR) from those transduced with non-transforming constructs (RELA-S276E, RELA FUS1 -S486E, and RELA FUS1 -EE), strongly suggesting that NF-κB activity is significantly associated with RELA FUS1 -driven tumorigenesis ( Figures 6A, S6A , and S6B). More than half of these genes were enriched for regulators of cell-cell adhesion and the extracellular matrix, immunity and inflammation, or vesicle trafficking (Table S4B) . Thus, RELA FUS1 might drive EPN tumorigenesis in part by dysregulating communication between tumor cells and the brain microenvironment, perhaps promoting local invasion and growth (Mohankumar et al., 2015) .
Interestingly, in addition to these gene sets, both PDGF beta polypeptide (PDGFB) and its cognate receptor PDGF beta polypeptide (PDGFRB) were markedly upregulated in the transcriptomes of RELA FUS1 -driven ex vivo and de novo ependymomas ( Figure 6B ; Parker et al., 2014) as well as selectively upregulated in those driven by tumorigenic RELA FUS1 mutants (Table S7) . PDGFB is a highly potent neural oncogene (Dai et al., 2001 ); thus, RELA FUS1 might also drive EPN tumorigenesis by upregulating oncogenic PDGFB-PDGFRB signaling.
The Normal Ventricular Wall as the Putative Location for Ependymomagenesis
Our prior cross-species analyses and ex vivo mouse modeling predict that neural stem cells in the lateral ventricular wall are cells of origin of EPN (Johnson et al., 2010; Mohankumar et al., 2015; Taylor et al., 2005) . However, these studies involved cross-species mapping of human EPN gene expression profiles in normal developing mouse brain or ex vivo transduction of mouse neural stem cells that form tumors when reimplanted in the brain. Therefore, to better understand the origin of ependymoma, we took advantage of our de novo RELA FUS1 -induced tumor model. These tumors were typically observed as intraand/or peri-ventricular cerebral masses, although, rarely, tumors also occurred in the cerebral parenchyma not obviously connected with the ventricular system, similar to the growth pattern of human ependymomas (Figures 2A, 2C , 3A, S2A, and S7A-S7E). Histological analyses of early lesions developing within 31 days of RELA FUS1 injection into N/tv-a mice identified small lesions immediately adjacent to the ventricular system ( Figures 7A and  S7E ).
To further understand the cellular origin of ependymoma, we tested the capacity of mice harboring different tv-a transgenes to develop RELA FUS1 -driven ependymoma. N/tv-a used in the experiments described above specifically targets nestin-expressing neural stem and progenitor cells. Therefore, we investigated the oncogenic potential of the RELA FUS1 gene in neonatal mouse brains when it is targeted to GFAP-expressing cells using (G)/tv-a- or BLBP (brain lipid binding protein, also known as fatty acid binding protein 7 or FABP7)-expressing cells using a (B)/tv-a transgenic mouse in which an expression of tv-a, a receptor for RCAS virus, was driven under a GFAP or BLBP promoter, respectively ( Figures S7F-S7H ). Tumors occurred in both of these transgenic lines with similar histologic features as those forming in the N/tv-a mice (or human ST-EPN) (Figures 7B and 7C; Table S1D ). These data further support the notion that Nestin-, GFAP-, and BLBP-expressing neural stem and progenitor cells in the ventricular wall can serve as cells of origin of RELA FUS1 -induced ST-ependymoma.
DISCUSSION
Unlike GBM with its multiple sequence and copy number alterations, the genome of human ST-EPN is relatively stable but contains a fusion gene that is sufficient to induce similar tumors in mice. Therefore, human ST-EPN may follow a single-hit oncogenesis model such as BCR-ABL-driven chronic myelogenous leukemia (CML) (Groffen et al., 1984) . The oncogenic function of the RELA or YAP1 fusion products in ST-EPN is not yet known, and it may or may not be easily targeted with small molecules. Genetically accurate mouse models of this disease will certainly help with the development of such therapies should they become available.
The location of the cell of origin of RELA FUS1 -EPN in the mouse seem to be at the edge of the subventrical zone (SVZ), consistent with what one might imagine for human STependymoma. At this point, it is not clear whether the oncogenic function of this fusion protein occurs in the nucleus or cytoplasm. When it comes to the driving functions of the RELA fusion products, RELA FUS1 does have NF-κB activity, but it is worth noting that neither the individual components of or activated versions of RELA form ependymomas. Several lines of evidence suggest that the oncogenic driving functions of RELA fusion products may be more than aberrant NF-κB activity. We found that RELA FUS1 drives several other biological processes, including vesicular transport, development of cytokine production, and cell-cell adhesion. The importance of cell-cell adhesion in the oncogenic effect of RELA FUS1 is further underscored by a series of mutant forms of RELA FUS1 , where expression programs affecting cell-cell adhesion specifically characterize mutants of this fusion oncogene. Further, only a subset of residues critical for RELA activity are essential for oncogenic activity of RELA FUS1 . Finally, the amount of PDGF and its receptor induced by RELA FUS1 in murine ST-EPN are comparable with the amounts of these proteins sufficient to drive oncogenesis in RCAS/tv-a mouse models of gliomas. It therefore seems possible that at least part of the oncogenic effect of RELA FUS1 in the CNS includes induction of PDGF signaling.
Our model faithfully recapitulated the histologic features and molecular profile of human RELA fusion-positive ependymomas. However, given that RELA fusions were generated by a chromothripsis event on chromosome 11, the gene rearrangement might affect the status of other genes on the chromosome with various degrees. Therefore, although RELA fusion alone is sufficient to form brain tumors in mice, the molecular mechanism underlying RELA fusion driven-tumorigenesis in humans could be more complex and influenced by other altered neighboring genes.
The emerging data regarding this tumor type provides the potential for diagnostic tests that clearly distinguish these tumors from other glial neoplasms. Immunohistochemical analysis of tumors revealed strong nuclear-localized RELA staining in the RELA FUS -positive EPN and less nuclear or even nuclear-excluded RELA staining in the case of other ependymomas and gliomas. Obviously a more direct measure of the presence of RELA FUS would be RT-PCR for the various possible mRNAs encoding these fusion proteins. Of course, creating such a set of diagnostic tools would be much more compelling when a therapeutic strategy aimed at the RELA FUS1 gene product has been developed.
EXPERIMENTAL PROCEDURES Human Tumor Samples and Patient Characteristics
Formalin-fixed paraffin-embedded (FFPE) human EPN samples (n = 120) were obtained from the Department of Pathology at the University of Washington (UW; Seattle, WA; n = 56), Kitasato University (Kanagawa, Japan; n = 51), and Kanazawa University (Kanazawa, Japan; n = 13). In addition, 30 samples of surgically resected World Health Organization (WHO) grade IV GBMs were retrieved from the University of Washington pathology archive and were utilized as control groups. These samples were diagnosed according to the WHO classification (Louis et al., 2016) and had IRB (institutional review board) approval at each institution (University of Washington; IR File 8305; Kanazawa University, 2015-010 [396] ; Kitasato University, B13-191) . Clinical and pathologic characteristics are summarized in Table S2A . Recurrent ependymomas were categorized in primary sites regardless of the recurrent location in this study. Several available frozen samples from Kitasato University were also used for RT-PCR detection of RELA FUS1 and RELA FUS2 .
Generation of Murine Brain Tumors
All animal experiments were done in accordance with protocols approved by the Institutional Animal Care and Use Committees of Fred Hutchinson Cancer Research Center (FHCRC) and followed NIH guidelines for animal welfare. The RCAS/tv-a system used in this work has been described previously (Holland et al., , 2000 Ozawa et al., 2014) . GFAP (G)/tv-a, Nestin (N)/tv-a (agouti), N/tv-a;Ink4a-Arf −/− ;Pten fl/fl , or BLBP (B)/tv-a mice were used for RCAS-mediated brain tumor formation in this study. Briefly, DF-1 cells were transfected with the indicated RCAS plasmid using XtremeGENE 9 DNA transfection reagent (Roche) according to the manufacturer's protocol. After checking RCAS expression with western blotting analysis, the cells (1 μL of 1 × 10 5 cells) were injected into newborn pup brains (within 3 days after birth). The mice were monitored until they developed symptoms of disease, such as lethargy, poor grooming, weight loss, dehydration, macrocephaly, seizures, jumping, and paralysis, or until 6 months after injection. Cases that failed to wean due to severe hydrocephalus caused by injection trauma and an inflammatory response against DF-1 cells were excluded from this study. Mouse brains were then used for subsequent analyses such as survival analysis, immunohistochemistry, and RNA-seq. Kaplan-Meier analysis demonstrating symptom-free survival of murine brain tumors was performed using log rank test in the Prism 7 software (GraphPad) for all mice injected with the relevant RCAS virus. Log rank p values were measured with the Mantel-Cox test. A value of p < 0.05 was considered significant in this study.
H&E Staining and Immunohistochemistry
Mouse brains were paraffin-embedded, sectioned, and stained with H&E as described previously (Hambardzumyan et al., 2009; Holland et al., 2000) . Immunohistochemical staining of mouse brains and human specimens was performed with an automated staining processor using the Discovery DAB Map Detection Kit according to standard protocols as described previously (Ventana Medical Systems, Tucson, AZ) (Hambardzumyan et al., 2008) . For ambiguous cases, the staining was repeated and carefully examined. Human STependymomas were stained at least twice. See also Supplemental Experimental Procedures.
Plasmids
All vectors used in this study are listed in Table S1E . The details of vector constructs are described in the Supplemental Experimental Procedures.
Western Blot Analysis
Cells were cultured, lysed, and processed for western blotting by standard methods. See also Supplemental Experimental Procedures.
RNA-Seq Analysis for Murine Brain Tumors and NIH 3T3T Cells
Tumor tissues and half normal forebrains were macroscopically dissected and quickly crushed in liquid nitrogen. Total RNAs for mouse tissues and NIH 3T3T cells were extracted with the RNeasy Mini Kit (QIAGEN) according to the manufacturer's protocol and then labeled and amplified with the Illumina protocol, followed by sequencing on Illumina HiSeq2500 at the Genomics Shared Resource at FHCRC. RNA-seq reads were aligned to the University of California, Santa Cruz (UCSC) mm10 assembly using Tophat2 (Kim et al., 2013) and counted for gene associations against the UCSC genes database with HTSeq. Batch effects were corrected using the R function combat from the R package swamp (https://cran.r-project.org/web/packages/swamp/index.html). Log2 normalized data were used for subsequent principal-component analysis, MDS, and GSEA in R. Differential expression analysis was performed using the R/Bioconductor package limma (Ritchie et al., 2015) . See also Supplemental Experimental Procedures.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. (C) Summary of semiquantitative immunohistochemical analysis for RELA in human ependymomas and GBMs. The immunoexpression level was evaluated using two criteria: nuclear immunoreactivity (NucIR) and staining intensity as described in Figure S3D and Table S2B . See also Supplemental Experimental Procedures. (Pajtler et al., 2015; Taylor et al., 2005) . The nominal p value (NOM shown in the legends and Table S1C. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (C) Tumor incidence of RELA-HA, RELA FUS1 -HA, or the relevant mutant injection in N/tv-a and N/tv-a;Ink4a-Arf −/− mice. See also Tables S1A-S1C.
